S-(hydroxymethyl)glutathione : An S-substituted glutathione that is glutathione in which the mercapto hydrogen has been replaced by a hydroxymethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 447123 |
| CHEBI ID | 48926 |
| SCHEMBL ID | 346451 |
| MeSH ID | M0093987 |
| Synonym |
|---|
| 32260-87-0 |
| S-HYDROXYMETHYLGLUTATHIONE , |
| s-(hydroxymethyl)glutathione |
| DB04153 |
| s-hydroxymethyl glutathione |
| CHEBI:48926 |
| SCHEMBL346451 |
| s-hydroxylmethylglutathione |
| PIUSLWSYOYFRFR-BQBZGAKWSA-N |
| (2s)-2-amino-4-{[(1r)-1-[(carboxymethyl)carbamoyl]-2-[(hydroxymethyl)sulfanyl]ethyl]carbamoyl}butanoic acid |
| s-hydroxymethyl-glutathione |
| l-gamma-glutamyl-s-(hydroxymethyl)-l-cysteinylglycine |
| Q27104637 |
| DTXSID901232201 |
| Role | Description |
|---|---|
| Escherichia coli metabolite | Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. |
| mouse metabolite | Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| S-substituted glutathione | A glutathione derivative that is glutathione in which the hydrogen of the thiol has been replaced by any other group. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Metabolism | 1496 | 1108 |
| Biological oxidations | 150 | 276 |
| Phase I - Functionalization of compounds | 69 | 175 |
| Ethanol oxidation | 12 | 16 |
| RuMP cycle, oxidative branch of the pentose phosphate pathway and formaldehyde assimilation | 1 | 12 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 3 (16.67) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||